The nicotinic receptors in the nervous system

Effects of muscarinic receptor agonists and antagonists on swim-stress-induced 'behavioural despair' in rats

The effects of some selective agonists and antagonists of cholinergic muscarinic receptor subtypes on swim-stress-induced immobility (SI) was investigated in rats. This paradigm has been proposed to assess 'behavioural despair' in rodents as a laboratory model for clinical depression. All the rats were pre-treated with atropine ethoiodide i.p. to obviate any peripheral cholinergic influence. SI was only marginally less in intracerebroventricular (i.c.v.) cannulated rats administered artificial cerebrospinal fluid than in uncan nulated rats administered normal saline i.p. The drugs which do not have access across the blood-brain barrier were administered i.c.v. The muscarinic M(1) receptor agonists, arecholine and McN-A-343, and the non-specific muscarinic receptor agonist, oxotremorine, induced dose-related increases in SI, whereas the muscarinic M(1) receptor antagonists, scopolamine and pirenzepine, and the non-specific antagonist, atropine, produced significant decreases in SI. Carbachol, an M(2) receptor agonist, and physostigmine induced a dose- dependent dual effect, with lower doses attenuating and higher doses augmenting SI. The M(2) receptor antagonists, gallamine and AF-DX 116, increased SI. The data may be interpreted to suggest that muscarinic M(1) receptors may function to accentuate depression whereas muscarinic M(2) receptors may exert an inhibitory modulatory effect.

Interaction of the hexamethonium derivative W84, an allosteric effector at muscarinic cholinoreceptors, with rat brain nicotinic binding sites

The hexamethonium derivative W84 (hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)-ammonium bromide]) combined with atropine has an overadditive protective action against organophosphorus intoxications. It affects allosterically the binding of (-) [3H]N-methylscopolamine [(3H]NMS) to muscarinic cholinoceptors. Because nicotinic receptors are involved in organophosphorus intoxications, the interaction of W84 with nicotinic cholinoceptors was investigated. (-) [3H]nicotine (2.5 nM) was used to label nicotinic binding sites in rat brain membranes in 50 nM Tris, pH 7.3 at 23 degrees. Under control conditions, (-) [3H]nicotine-binding revealed a KD of 4 X 10(-9) M and a Bmax of 53 fmol/mg membrane protein. W84 inhibited (- ) [3H]nicotine-binding with an IC50 of 3 X 10(-5) M by reducing the binding affinity. The IC50 of hexamethonium was 20 X 10(-5) M. At 10(-4) M, W84 did not affect the dissociation rate of (-)[3H]nicotine, suggesting a lack of allosteric activity. For sake of comparison, the action of W84 was checked on [3H]NMS-binding (control: KD approximately 1 X 10(-9) M, Bmax approximately 500 fmol/mg prot). W84 inhibited the binding of [3H]NMS (0.5 nM) with an IC50 of 1.5 X 10(-9) M. At 10(-4) M, W84 prevented [3H]NMS-dissociation almost completely, thus displaying the allosteric action at muscarinic cholinoceptors. In conclusion, the results of the (-)[3H]nicotine-binding experiments point to a pure competitive action of W84 at nicotine cholinoceptors, lacking any allosteric effect. This competitive action may contribute to the protective effect of W84 in organophosphorus poisoning.

Oxiracetam prevents mecamylamine-induced impairment of active, but not passive, avoidance learning in mice

The nicotinic antagonist mecamylamine (2.5 and 5 mg/kg/IP) depressed both active (shuttle-box) and passive (step-through) avoidance learning in mice of the DBA/2 strain. The nootropic drug oxiracetam (50 and 100 mg/kg/IP) improved acquisition in the multitrial active avoidance test, but had no effect on one-trial passive avoidance learning. When the two drugs were combined, oxiracetam did not counteract mecamylamine-induced impairment of passive avoidance learning, even if it maintained a facilitating action on shuttle-box avoidance acquisition in mice receiving the nicotinic receptor blocker. Prevention of mecamylamine-induced shuttle-box avoidance depression by oxiracetam indicates that central nicotinic mechanisms are probably involved in the improving effects exerted by nootropic drugs on learning.

Molecular cloning of human neuronal nicotinic receptor alpha 3-subunit

Neuronal nicotinic receptors (nAchRs) have been isolated or cloned in insect, bird and mammalian neurons, but no information exists on the primary structure of human neuronal nAchRs. By screening a cDNA library from the human neuroblastoma cell line IMR 32 with a cDNA probe corresponding to the full length of rat alpha 3-nicotinic subunit, we have identified an open reading frame encoding a protein of 502 amino acids. This protein shows all the features of members of the ligand-gated receptor superfamily and has two cysteine residues at positions 192, 193 which are typical of the nicotinic alpha-subunits. Because of its high homology to rat alpha 3 (93% amino acid identity), we conclude that we have cloned the human alpha 3-nicotinic subunit.